BERLIN--(BUSINESS WIRE)--NOXXON Pharma AG (NOXXON), developer of mirror image oligonucleotide therapeutics termed Spiegelmers®, announced today the successful closing of a 37 million Euro (50 million US $) series C round of financing. The main new investors were TVM Capital, Sofinnova Partners, and Edmond de Rothschild Investment Partners, who are represented on the Board. They were joined by Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG (DEWB) as existing lead investor, FCP OP MEDICAL BioHealth-Trends (advised by Medical Strategy GmbH) and the Dieckell Group, as well as new investors Seventure, Dow Venture Capital - a unit of The Dow Chemical Company -, IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH, VC Fonds Berlin GmbH, and others to provide the funding for the pre-clinical and clinical development of NOXXON’s lead products in kidney disease and ophthalmology.
